Peter S. Whitton

Exenatide and the treatment of patients with Parkinson’s disease

Icíar Avilés-Olmos, John Dickson, Zinovia Kefalopoulou et al. · Journal of Clinical Investigation · 2013 · 494 citations

Motor and Cognitive Advantages Persist 12 Months After Exenatide Exposure in Parkinson’s Disease

Icíar Avilés-Olmos, John Dickson, Zinovia Kefalopoulou et al. · Journal of Parkinson s Disease · 2014 · 291 citations · Full text

Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists

G.A. Kennett, Peter S. Whitton, K. Shah et al. · European Journal of Pharmacology · 1989 · 283 citations

Signal Transduction, Functional Selectivity, Medicine +10

Glucagon-like peptide 1 receptor stimulation reverses key deficits in distinct rodent models of Parkinson's disease

Alexander Harkavyi, Amjad Abuirmeileh, Rebecca Lever et al. · Journal of Neuroinflammation · 2008 · 281 citations · Full text

Biphasic modulation of GABA release by nitric oxide in the hippocampus of freely moving rats in vivo

Stephen J. Getting, Joanna Segieth, Shagufta Ahmad et al. · Brain Research · 1996 · 109 citations

Biphasic Modulation, Neurophysiology, Nitric Oxide +13